Risk factors for HIV infection among men who have sex with men in the ANRS IPERGAY PrEP trial.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
08 2022
Historique:
received: 28 06 2021
accepted: 18 09 2021
pubmed: 20 10 2021
medline: 28 7 2022
entrez: 19 10 2021
Statut: ppublish

Résumé

We aimed to assess among men who have sex with men (MSM) risk factors for HIV infection, to identify those who require urgent pre-exposure prophylaxis (PrEP) prescription. All participants enrolled in the placebo arm of the ANRS IPERGAY trial, or infected between screening and day 0, were included. Baseline characteristics were described and HIV incidence rate ratios (RRs) were estimated with their 95% CIs. 203 MSM were included with a median follow-up of 9 months. During the study period, 16 participants acquired HIV infection while not receiving tenofovir disoproxil and emtricitabin (TDF/FTC) over 212.4 person-years (PYs) of follow-up (incidence rate 7.5/100 PYs, 95% CI: 4.3 to 12.2). Being enrolled in Paris was associated with a significant increased risk of HIV infection (RR: 4.1; 95% CI: 1.1 to 28.3). A high number of sexual partners in prior 2 months (≥10 vs MSM who have frequent condomless receptive anal sex and multiple partners, or use recreational drugs should be targeted in priority for PrEP prescription especially if they live in an area with a high prevalence of HIV infection.

Identifiants

pubmed: 34663696
pii: sextrans-2021-055199
doi: 10.1136/sextrans-2021-055199
doi:

Substances chimiques

Anti-HIV Agents 0
Illicit Drugs 0
Emtricitabine G70B4ETF4S

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-386

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Julien Gras (J)

Infectious Diseases Department, Saint-Louis Hospital, Paris, France julien.gras@aphp.fr.
INSERM U944 « Biology of Emerging Viruses » team, Saint Louis Research Institute, Paris, France.

Marine Pillet (M)

SC10-US19, INSERM, Villejuif, France.

Guillemette Antoni (G)

SC10-US19, INSERM, Villejuif, France.

Eric Cua (E)

Department of Infectious Diseases, CHU Nice, Nice, France.

Isabelle Charreau (I)

SC10-US19, INSERM, Villejuif, France.

F Raffi (F)

Infectious Diseases Department, CHU Nantes, Nantes, France.

Christian Chidiac (C)

Infectious Diseases Department, University of Lyon, Lyon, France.

Julie Chas (J)

Infectious Diseases Department, Tenon Hospital, Paris, France.

Cécile Tremblay (C)

Microbiology, Montreal Sacre-Coeur Hospital, Montreal, Quebec, Canada.

Bruno Spire (B)

INSERM UMR 912 SESSTIM, Aix-Marseille University, Marseille, France.

Constance Delaugerre (C)

INSERM U944 « Biology of Emerging Viruses » team, Saint Louis Research Institute, Paris, France.
Virology Department, Saint-Louis Hospital, Paris, France.

Laurence Meyer (L)

SC10-US19, INSERM, Villejuif, France.

Jean-Michel Molina (JM)

Infectious Diseases Department, Saint-Louis Hospital, Paris, France.
INSERM U944 « Biology of Emerging Viruses » team, Saint Louis Research Institute, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH